Biomerica, Inc. announced on October 16, 2025 that its first‑quarter fiscal 2026 results ended August 31, 2025 showed net sales of $1.4 million, down from $1.8 million in the same quarter of fiscal 2025, reflecting weaker retail activity and international order timing. The company’s gross profit increased, driven by a more favorable product mix and higher‑margin contract manufacturing services, while operating expenses fell to $1.5 million from $1.7 million, improving the operating loss to $1.1 million versus $1.4 million previously. Net profit for the quarter was approximately $2,000, a turnaround from a $1.3 million loss in the prior year’s quarter. The release highlighted that sales of the inFoods IBS diagnostic‑guided therapy rose, offsetting some of the decline in other segments, and underscored Biomerica’s continued focus on cost discipline and selective investment in core diagnostic programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.